 |
|
 |
|
 |
 |
 |
|
|||
NewsProteostasis Therapeutics Announces Addition of Key Executive -- Peter H. Reinhart Joins as CSO -- March 25, 2010, Cambridge, Mass. - Proteostasis Therapeutics announced today the appointment of Peter H. Reinhart, Ph.D., as Chief Scientific Officer. Dr. Reinhart replaces interim CSO, Walter Newman, Ph.D., of Healthcare Ventures, who will remain with the company as a consultant. “Proteostasis is poised to translate its cutting-edge science into important advancements in discovery medicine. This key addition to our senior management team will provide leadership as we apply our proprietary drug discovery platform to moving novel small molecule therapeutics forward,” said Christopher Mirabelli, Ph.D., Chairman of the Board of Proteostasis. “Peter brings extensive scientific leadership in successfully moving several first-in-class, disease-modifying compounds for neurodegenerative diseases from discovery research into clinical development.” Dr. Reinhart previously oversaw Neurodegeneration Research at Wyeth Pharmaceuticals and Pfizer, focusing on Alzheimer’s disease, Parkinson’s disease, stroke programs and ALS. During his six-year tenure there, Dr. Reinhart delivered numerous drug candidates into clinical development. Prior to joining Wyeth, he served as Vice President, Neurodegeneration at Cogent Neuroscience after twelve years as a faculty member at Duke University Medical Center, where he continues to serve as an adjunct professor. Dr. Reinhart is a member of the Scientific Advisory Board at the Michael J. Fox Foundation for Parkinson’s Research. Dr. Reinhart received a B.Sc. and Ph.D. in Biochemistry from the Australian National University and did his postdoctoral training in Neurobiology at University Tuebingen, Germany. He has authored more than 90 publications, and serves as a scientific reviewer for Science, Neuron, Nature Drug Discovery, Journal of Neuroscience and Molecular Pharmacology. About Proteostasis Therapeutics, Inc. Proteostasis Therapeutics is discovering “Proteostasis Regulators” (PRs), small molecule drugs that restore proper protein function to treat neurodegenerative, metabolic, genetic and inflammatory disorders. The Proteostasis Network (PN) is the cellular machinery responsible for protein folding, trafficking and clearance, and it can become imbalanced by the cumulative effects of aging, disease and genetics. PTI was founded by leading scientists who discovered a pioneering approach for treating disease by restoring protein network homeostasis. www.proteostasis.com Contacts: Media: |
|||